Liraglutide
SCALE™ IBT
Novo Nordisk · Phase 3 · Completed · Enrollment 282
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Liraglutide | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
| Liraglutide 3.0 mg, in trial | 61.47% | 30.45% | 18.11% | n/r |
| Placebo, in trial | 38.82% | 19.75% | 8.92% | n/r |
Not shown
- Liraglutide: endpoint not reported
- Placebo: endpoint not reported